Disruptive Innovation in Life Sciences

What We Do

PHD Biosciences (PHD) is a clinical-stage biopharmaceutical company developing a pipeline of in-house and in-licensed technologies for oncology and hematology.  Our team comprises world renowned experts in drug development and has collectively raised in excess of $300 million to fund the development of several drug products through registration. Additionally, since 2011 PHD programs have won 16 awards totaling more than $9.5 million in non-dilutive financing to support the development of technologies for a variety of indications.

When in-licensing technologies, the involvement of the academic principal investigator (PI) is important to us and we engage in a collaborative model, through university sub-contracts and other mechanisms, that helps secure the PI’s involvement through the development and commercialization process.   An initial investment in new programs is financed 100% in-house, and promising technologies are advanced using combinations of non-dilutive and dilutive funding.

Grant Awards

institutes

million in non-dilutive funding

Our Team

Our team comprises experts with experience in drug development, operations, business development, regulatory affairs, planning, finance, and drug product registration.

Steven Isaacman, Ph.D.

Dr. Isaacman founded PHD Biosciences in 2008, and currently serves as the CEO where he manages the development of the companies therapeutic programs.  He is an expert in the development and commercialization of drug products, has been responsible for the invention and management of collaborative efforts that have lead to the commercialization of several drug- and non-drug products, which are currently sold globally, and has been the Principal Investigator on 16 of PHD’s awards since 2011.  He is also an Assistant Professor of Medicine in the Department of Hematology & Biophysics at the Albert Einstein College of Medicine and a Visiting Scholar in the chemistry department at New York University.  He received his Ph.D. in organic chemistry from New York University, and M.S. and B.S. degrees in chemistry and biochemistry from Stony Brook University.

FOUNDER & CEO
Andrew Mahon, Ph.D.

Dr. Mahon is the Chief Scientific Officer (CSO) at PHD Biosciences. With over 15 years of experience in medicinal chemistry and chemical biology, he manages drug development and basic research within the company.  He is directly involved in experimental design, and implementation and assists the CEO in managing employees and overall corporate strategy. He has also been instrumental in raising over $4M in funding to accelerate the translational development of the companies preclinical and clinical stage assets. He is also an Assistant Professor of Medicine in the department of Hematology & Biophysics at the Albert Einstein College of Medicine and a Visiting Scholar in the  department of Chemistry at New York University.

CSO
Michael Isaacman, Ph.D.

Dr. Isaacman is Director of Research at PHD Biosciences, and manages programs that center around wet lab activities and include polymer and small molecule synthesis.  He received his Ph.D. from the University of California, Santa Barbara where his research focused on the synthesis and self-assembling dynamics of silicone-based amphiphilic block co-polymers. Michael is an expert in synthetic chemistry and has pioneered novel methodologies for the design & fabrication of moieties for use in drug delivery and over-the-counter drug products  Michael has 10 years of experience in the fields of natural product synthesis, polymer synthesis, nanoparticle self-assembly, and topical drug delivery.

DIRECTOR R&D
Michael Szarek, Ph.D.

Dr. Szarek leads Regulatory Affairs, is the company’s representative to FDA, and maintains open INDs. He has been involved in the design, conduct, and analysis of numerous cardiovascular and oncology clinical trials.  This includes SPARCL, a landmark study where 4,731 patients with a history of cerebrovascular disease were treated with atorvastatin or placebo and followed for the occurrence of cardiovascular events.  He is currently a member of the Executive Steering Committee of the Odyssey Outcomes Study, which is comparing the effect of alirocumab with placebo on the occurrence of cardiovascular events in 18,000 patients who have experienced an acute coronary syndrome (ACS) event prior to randomization.  He has also served on Data Monitoring Committees for Phase 3 studies, and has written protocols, analysis plans, Committee charters, and study reports for multiple studies in various therapeutic areas across all stages of clinical development.  In his prior and current positions in regulatory affairs, he has also been responsible for initial IND submissions and amendments to open INDs.

REGULATORY AFFAIRS
Eric Rowinsky, M.D.

Dr. Rowinsky is a world-renowned expert on the development and registration of therapeutics with approximately 25 years of experience in the academic sector and biopharmaceutical industry.   He has focused on the comprehensive development and registration of novel oncology therapeutics since his seminal clinical and preclinical studies of paclitaxel.  These initial studies were the foundation for the ultimate approval of the first blockbuster drug in cancer, and registration in cancers of the ovary, lung, head and neck, and breast in the early 1990s.  He has played a major role in  development strategies leading to the worldwide registration of paclitaxel, docetaxel, irinotecan, topotecan, erlotinib, gefitinib, panitumumab, temsirolimus, and trabectedin, amongst others.    He previously served as the Head of Research and Development and Chief Medical Officer at Stemline Therapeutics Inc., during which time, he was integrally involved with raising approximately $160 Million and a public offering, which launched its principal therapeutic cancer stem cell targeting assets into various worldwide pivotal clinical trials.

CLINICAL OPERATIONS
Scott Spector

Mr. Spector is an accomplished clinical development executive with 20 years of pharmaceutical product development experience.  He was previously the European President of Siro Clinpharm, an emerging market CRO with a strong emphasis on the CEE and India.  His career in clinical development started at Quintiles Transnational, where he was instrumental in leading the growth of the company’s European operations.  Scott served as the President of Quintiles France and Spain and was also the global operations head of the CNS and Anti-Infectives business units.  Following a 10-year career at Quintiles, he became President of CAC Oncology, an early pioneer in oncology contract research services and drug development consulting. Upon the sale of CAC Oncology to AAIPharma, he became President of a newly created entity called AAI Oncology.  He holds a BS/BA in Finance from Boston University and a Professional Certificate in Genetics and Genomics from Stanford University.

CLINICAL OPERATIONS

Recent News

For older news items, please click HERE.

phd expands on collaboration with grant industries inc.

PHD Biosciences has recently initated an expanded collaboration with Grant Industries Inc. to develop new polymers for a variety of dermatology indications.

PHD COMPLETES ACQUISTION OF UTC FROM FORTRESS BIOTECHNOLOGY

PHD Biosciences has completed its acquistion of the “Fast Track” Uracil Topical Cream (UTC) clinical asset from Fortress Biotechnology, and is preparing to initiate a pivotal study in 100 patients with metastatic breast cancer.

PHD WINS $2 MILLION FROM NCI

PHD Biosciences has won a $2 million Direct Phase II SBIR award from the National Cancer Institute to fund a pivotal clinical trial for its lead clincial asset.

Contact Us

PHD Biosciences HQ

180 Varick Street, Suite 526

New York, NY 10014

12 + 2 =